| Target Price | ¥2,550.00 |
| Price | ¥2,246.50 |
| Potential |
13.51%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Hamamatsu Photonics Kk 2027 .
The average Hamamatsu Photonics Kk target price is ¥2,550.00.
This is
13.51%
register free of charge
¥3,465.00
54.24%
register free of charge
¥1,414.00
37.06%
register free of charge
|
|
| A rating was issued by 13 analysts: 7 Analysts recommend Hamamatsu Photonics Kk to buy, 5 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Hamamatsu Photonics Kk stock has an average upside potential 2027 of
13.51%
register free of charge
|
| Sep '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 212.05 | 237.25 |
| 3.97% | 11.89% | |
| EBITDA Margin | 10.32% | 19.46% |
| 41.68% | 88.49% | |
| Net Margin | 6.70% | 7.44% |
| 45.67% | 11.08% |
10 Analysts have issued a sales forecast Hamamatsu Photonics Kk 2026 . The average Hamamatsu Photonics Kk sales estimate is
This results in the following potential growth metrics:
10 Hamamatsu Photonics Kk Analysts have issued a net profit forecast 2026. The average Hamamatsu Photonics Kk net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Sep '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 47.32 | 61.05 |
| 41.71% | 29.02% | |
| P/E | 36.80 | |
| EV/Sales | 2.86 |
10 Analysts have issued a Hamamatsu Photonics Kk forecast for earnings per share. The average Hamamatsu Photonics Kk EPS is
This results in the following potential growth metrics and future valuations:
Hamamatsu Photonics Kk...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


